One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented at the American Association for Cancer Research conference.
One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented Sunday at the American Association for Cancer Research conference in Philadelphia.
One study, comparing Keytruda to Bristol-Myers Squibb Co's Yervoy, could give Merck a temporary advantage as the rivals battle for market supremacy and billions of dollars in annual sales from this new generation of drugs, which help the immune system destroy cancer cells. While research continues, the pace is quickening and big improvements in patient care regimens are likely fairly soon.
Read more from the Associated Press and ABC News: http://abcn.ws/1D8z4z3
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More